Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : The net proceeds will advance integrated computational design-synthesis platform for next-generation peptide drug discovery. The platform is designed to address previously undruggable targets, accelerate discovery and enhance the quality of peptide drug ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
Details : Under the collaboration, ShapeTX will use its proprietary AI-powered RNA editing platform to develop a potential one-time therapy for patients with high unmet needs for an undisclosed disease affecting millions of people worldwide.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Preclinical
Sponsor : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Discovery Platform
Sponsor : Otsuka Pharmaceutical
Deal Size : $1,500.0 million
Deal Type : Collaboration
Otsuka Collaborates with ShapeTX to Develop Novel AAV Gene Therapies for Ocular Diseases
Details : The companies will collaborate to apply ShapeTX’s AAVid™ capsid discovery platform and transgene engineering technology along with Otsuka’s expertise in genetic payload design and ophthalmology to develop novel treatment options for people living w...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Discovery Platform
Sponsor : Otsuka Pharmaceutical
Deal Size : $1,500.0 million
Deal Type : Collaboration
Details : The data to be presented at ASGCT demonstrates the impact that AI has on the discovery and delivery of the next generation of RNA based medicines,fine-tune gene expression, and modulate protein interactions.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $3,000.0 million
Deal Type : Collaboration
Details : During the course of the partnership, ShapeTX will conduct preclinical research to identify and deliver development candidates discovered by its AI-powered platforms RNAfix™ and, potentially, AAVid™.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : F. Hoffmann-La Roche
Deal Size : $3,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Decheng Capital
Deal Size : $112.0 million
Deal Type : Series B Financing
Details : ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership oppo...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Decheng Capital
Deal Size : $112.0 million
Deal Type : Series B Financing